The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.
January
Sensus Healthcare is excited to attend the 2024 Fall Clinical…
January
Keloid recurrence rate of 10.4% at 12 months for patients…
January
Recently, a study was conducted on the efficacy of the…
January
Recently, Sensus Healthcare’s CEO, Joe Sardano, was featured on a…
January
What Are the Types of Non-Melanoma Skin Cancer? First, for…
